PPBT
NASDAQPurple Biotech Ltd.
Price$2.90-1.98 (-40.55%)
2026-03-092026-06-10
News · 26 weeks31-50%
2025-12-142026-06-07
Mix2490d
- Other8(33%)
- Insider8(33%)
- SEC Filings7(29%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
- PRPurple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic WindowNon-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant IM1240 demonstrated anti-tumor activity across PD-1- and chemotherapy-resistant patient-derived tumor samples in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a key contributor to this anti-tumor efficacy IM1240 induced immune cell structures associated with effective anti-tumor responses and a favorable prognosis in patient-derived non-small cell lung cancer (NSCLC) explants REHOVOT, Israel, June 11, 2026 (GLOBE NEW
- SECSEC Form F-3 filed by Purple Biotech Ltd.F-3 - PURPLE BIOTECH LTD. (0001614744) (Filer)
- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
- PRPurple Biotech Reports First Quarter 2026 Financial Results and Business HighlightsNew data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Comp
- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
- PRPurple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all samples and improved the therapeutic index Immune cell structures known as a hallmark of effective anti-tumor immune response and favorable prognosis, were induced by IM1240 in a patient-derived non-small cell lung cancer (NSCLC) biopsy, corresponding with IM1240 anti-tumor efficacy REHOVOT, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Compa
- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
- PRPurple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody PlatformScientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3's advancement toward clinical-stage immunotherapy development SAB leverages expertise in translational science, NK and T cell biology REHOVOT, Israel and BOSTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer efficacy while minimizing toxicity, today announced the establishment of a SAB, including world-renowned experts, to advise the Company on the development of candidates from its
- INSIDERSEC Form 3 filed by new insider Rock Simcha3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zilberberg Suzana3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- INSIDERSEC Form 3 filed by new insider Agmon Ido3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- INSIDERSEC Form 3 filed by new insider Efron Gil3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Lankry Shai S3/A - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schickler Michael3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lankry Shai S3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
- PRPurple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody PlatformCollaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery timelines and enhance molecule quality for drug candidates targeting solid tumors REHOVOT, Israel and BOSTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug di
- INSIDERSEC Form 3 filed by new insider Gagnon Robert E.3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)
- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
- PRPurple Biotech Regains Compliance with NasdaqMinimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the "Listing Qualifications Department") that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market ("Nasdaq"), and is now compliant with applicable listing stand
- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
- PRPurple Biotech Announces CEO TransitionGil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed
- PRPurple Biotech Reports Fourth Quarter and Full Year 2025 Financial ResultsFocus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting TROP2 Achieved toxicology and manufacturing milestones for IM1240, demonstrating an expanded therapeutic window and commercially viable yield Positive preclinical data presented at ESMO Immuno-Oncology Congress 2025 demonstrates multi-arm anti-tumor activity for both IM1240 and IM1305 Total Cash Position of $9.5 million as of December 31, 2025, expected to provide runway into 2027 REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech"
- SECSEC Form 6-K filed by Purple Biotech Ltd.6-K - PURPLE BIOTECH LTD. (0001614744) (Filer)
PPBT FAQ
6 questionsWhat does Purple Biotech Ltd. do?
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2...Where does PPBT stock trade?
Purple Biotech Ltd. (PPBT) is listed on NASDAQ.What sector and industry is PPBT in?
Purple Biotech Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Purple Biotech Ltd. go public?
Purple Biotech Ltd. (PPBT) completed its IPO in 2015.What companies are similar to PPBT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PPBT side-by-side with any of them on Quantisnow.How can I track PPBT on Quantisnow?
Quantisnow aggregates Purple Biotech Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PPBT to receive live email and push alerts on every new disclosure.